Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: chemical strategies to prepare glycoconjugates with good carbohydrate loading
- PMID: 20340043
- DOI: 10.1007/s10719-010-9287-0
Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: chemical strategies to prepare glycoconjugates with good carbohydrate loading
Abstract
In previous studies protective antibodies that could facilitate bactericidal killing of Neisseria meningitidis (Nm) serogroup B strains were derived from immunisation with glycoconjugates prepared from O-deacylated lipopolysaccharide (LPS-OH) via direct reductive amination between the reducing end of the oligosaccharide molecule, created by treatment with alkaline phosphatase, and amino functionalities on the CRM(197) carrier protein. These glycoconjugates proved difficult to prepare because the presence of amide linked fatty-acyl groups results in glycolipids that are relatively insoluble and aggregate. Therefore, we have examined several strategies to prepare glycoconjugates in order to identify a robust, consistently reproducible strategy that produces glycoconjugates with a high loading of LPS derived oligosaccharides. Initially we used completely deacylated LPS molecules, but lacking phosphoethanolamine (PEtn) from the core OS as the strong basic conditions required to completely deacylate the LPS would modify the PEtn residue. We utilised a squarate linker and conjugated via the reducing end of the carbohydrate antigen following removal of the glycosidic phosphate to amino groups on CRM(197), however carbohydrate loading on the carrier protein was low. Glycoconjugates were then produced utilising amidases produced by Dictyostelium discoideum (Dd), which partially remove N-linked fatty acids from the lipid A region of the Nm LPS molecule, which enabled the retention of the PEtn residue. LPS-OH was treated with Dd amidase, the reducing glycosidic phosphate removed, and using a cystamine linker strategy, conjugated to the carrier protein. Carbohydrate loading was somewhat improved but still not high. Finally, we have developed a novel conjugation strategy that targets the amino functionality created by the amidase activity as the attachment point. The amino functionality on the PEtn residue of the inner core was protected via a novel blocking and unblocking strategy with t-butyl oxycarbonyl. A maleimide-thiol linker strategy, targeting lysine residues on the carrier protein did not result in high loading of the carbohydrate molecules, however when we targeted the carboxyl residues we have consistently obtained a high loading of carbohydrate antigens per CRM(197), which can be controlled by variation in the amount of activated carbohydrate utilised in the conjugation reaction.
Similar articles
-
Investigating the potential of conserved inner core oligosaccharide regions of Moraxella catarrhalis lipopolysaccharide as vaccine antigens: accessibility and functional activity of monoclonal antibodies and glycoconjugate derived sera.Glycoconj J. 2011 May;28(3-4):165-82. doi: 10.1007/s10719-011-9332-7. Epub 2011 May 18. Glycoconj J. 2011. PMID: 21590368
-
Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: conjugates based on core oligosaccharides.Glycoconj J. 2014 Jan;31(1):25-39. doi: 10.1007/s10719-013-9500-z. Epub 2013 Sep 7. Glycoconj J. 2014. PMID: 24013955
-
Investigating the candidacy of lipopolysaccharide-based glycoconjugates as vaccines to combat Mannheimia haemolytica.Glycoconj J. 2011 Aug;28(6):397-410. doi: 10.1007/s10719-011-9339-0. Epub 2011 Jun 24. Glycoconj J. 2011. PMID: 21701793
-
[Neisseria meningitidis. The pathophysiological role of lipopolysaccharides in association with meningococcal disease and septic shock].Ugeskr Laeger. 2008 Feb 4;170(6):421-6. Ugeskr Laeger. 2008. PMID: 18252172 Review. Danish.
-
Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.Expert Rev Vaccines. 2009 May;8(5):529-42. doi: 10.1586/erv.09.18. Expert Rev Vaccines. 2009. PMID: 19397410 Review.
Cited by
-
Investigating the potential of conserved inner core oligosaccharide regions of Moraxella catarrhalis lipopolysaccharide as vaccine antigens: accessibility and functional activity of monoclonal antibodies and glycoconjugate derived sera.Glycoconj J. 2011 May;28(3-4):165-82. doi: 10.1007/s10719-011-9332-7. Epub 2011 May 18. Glycoconj J. 2011. PMID: 21590368
-
Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: immunology of glycoconjugates with high carbohydrate loading.Glycoconj J. 2010 Oct;27(7-9):643-8. doi: 10.1007/s10719-010-9309-y. Epub 2010 Oct 5. Glycoconj J. 2010. PMID: 20922476
-
Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: conjugates based on core oligosaccharides.Glycoconj J. 2014 Jan;31(1):25-39. doi: 10.1007/s10719-013-9500-z. Epub 2013 Sep 7. Glycoconj J. 2014. PMID: 24013955
-
Naturally acquired antibodies against Haemophilus influenzae type a in Aboriginal adults, Canada.Emerg Infect Dis. 2015 Feb;21(2):273-9. doi: 10.3201/eid2102.140722. Emerg Infect Dis. 2015. PMID: 25626129 Free PMC article.
-
Meningococcal Vaccines: Current Status and Emerging Strategies.Vaccines (Basel). 2018 Feb 25;6(1):12. doi: 10.3390/vaccines6010012. Vaccines (Basel). 2018. PMID: 29495347 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical